Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q1 2023 · 10-Q
Revenue$5.82M$5.82M+48.3% vs Q1 2022 Net Income-$3.73M-$3.73MN/M vs Q1 2022 EPS Diluted-$0.10-$0.10N/M vs Q1 2022 Gross Profit$1,761,499+36.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flow-$4,103,827N/M Free Cash Flowderived-$4,114,398N/M Margins · derivedGross margin30.3%−2.6 pt vs Q1 2022
Operating margin-59.3%+85.4 pt vs Q1 2022
Net margin-64.0%+88.6 pt vs Q1 2022
ended Mar 31, 2023 · filed Jun 6, 2023 · 67 d after period end